MIRA INFORM REPORT

 

 

Report Date :

28.01.2013

 

IDENTIFICATION DETAILS

 

Name :

CHIROGATE INTERNATIONAL INC.

 

 

Registered Office :

No.41, LN. 298, & No.22, Aly. 39, Ln. 298, Gong 2nd Rd., Longtan Township, Taoyua County 32559

 

 

Country :

Taiwan

 

 

Date of Incorporation :

15.11.1999

 

 

Com. Reg. No.:

70452890

 

 

Legal Form :

Joint Stock Company

 

 

Line of Business :

Manufacture and sales of BPC(bulk pharmaceutical chemicals)

 

 

No. of Employees :

About 50 employees

 

RATING & COMMENTS

 

MIRA’s Rating :

Ba

 

RATING

STATUS

PROPOSED CREDIT LINE

41-55

Ba

Overall operation is considered normal. Capable to meet normal commitments.

Satisfactory

 

Status :

Satisfactory

Payment Behaviour :

No Complaints

Litigation :

Clear

 

NOTES :

Any query related to this report can be made on e-mail: infodept@mirainform.com while quoting report number, name and date.

 

ECGC Country Risk Classification List – June 30th, 2012

 

Country Name

Previous Rating

(31.03.2012)

Current Rating

(30.06.2012)

Taiwan

A2

A2

 

Risk Category

ECGC Classification

Insignificant

 

A1

Low

 

A2

Moderate

 

B1

High

 

B2

Very High

 

C1

Restricted

 

C2

Off-credit

 

D

 


 

Taiwan - ECONOMIC OVERVIEW

 

Taiwan has a dynamic capitalist economy with gradually decreasing government guidance of investment and foreign trade. In keeping with this trend, some large, state-owned banks and industrial firms have been privatized. Exports, led by electronics, machinery, and petrochemicals have provided the primary impetus for economic development. This heavy dependence on exports exposes the economy to fluctuations in world demand. In 2009, Taiwan's GDP contracted 1.9%, due primarily to a 20% year-on-year decline in exports. In 2010 GDP grew 10.9%, as exports returned to the level of previous years, and in 2011, grew 5.2%. However, 2012 growth will likely be less, according to most forecasters, because of softening global demand. Taiwan's diplomatic isolation, low birth rate, and rapidly aging population are major long-term challenges. Free trade agreements have proliferated in East Asia over the past several years, but so far Taiwan has been excluded from this greater economic integration largely because of its diplomatic status with the exception of the landmark Economic Cooperation Framework Agreement (ECFA) signed with China in June 2010. The MA administration has said that the ECFA will serve as a stepping stone toward trade pacts with other regional partners, and negotiations on a deal with Singapore began this year. Follow-on components of ECFA, including deals on trade in goods, services, and investment, have yet to be completed. Taiwan's Total Fertility rate of just over one child per woman is among the lowest in the world, raising the prospect of future labor shortages, falling domestic demand, and declining tax revenues. Taiwan's population is aging quickly, with the number of people over 65 accounting for 10.9% of the island's total population as of 2011. The island runs a large trade surplus, and its foreign reserves are the world's fourth largest, behind China, Japan, and Russia. Since 2005 China has overtaken the US to become Taiwan's second-largest source of imports after Japan. China is also the island's number one destination for foreign direct investment. Three financial memorandums of understanding, covering banking, securities, and insurance, took effect in mid-January 2010, opening the island to greater investments from the mainland's financial firms and institutional investors, and providing new opportunities for Taiwan financial firms to operate in China. Closer economic links with the mainland bring greater opportunities for the Taiwan economy, but also poses new challenges as the island becomes more economically dependent on China while political differences remain unresolved.

 

Source : CIA


 

Contact Points

 

Company Name:

CHIROGATE INTERNATIONAL INC.

Supplied Name:

CHIROGATE INT'L INC

Trading Address:

No.2, Shih 4th Rd., Youth Industrial Park, Yangmei Township,

Taoyuan County 32657, Taiwan

Supplied Address:

2 Shih 4th Rd Yangmei Chen Taoyuan Hsien 326

Telephone Number:

+886-3-496-3808

Fax Number:

+886-3-496-3800

E-mail:

sales@chirogate.com ; kirogate@ms63.hinet.net

Notes: Subject’s exact name and address are as above.

 

Company Identification Details

 

Registered Name:

CHIROGATE INTERNATIONAL INC.

Registered Address:

No.41, LN. 298, & No.22, Aly. 39, Ln. 298, Gong 2nd Rd., Longtan Township, Taoyua County 32559, Taiwan

Date of Foundation:

1999-11-15

Registration Number:

70452890

Registry:

Central Region Office, Ministry of Economic Affairs

Registered Capital:

NTD 236,000,000 (USD 8,000,400)

(As of 2013.01, 1 NTD = 0.0339 USD)

Paid-up Capital:

NTD 235,965,560 (USD 7,999,232)

Legal Representatives:

Fanggui Wei

Legal Form:

Joint Stock Company

Principal Activities:

Manufacture and sales of BPC(bulk pharmaceutical chemicals)

Staff:

About 50 employees

Listed at Stock Exchange:

No

Date of Last Annual Return:

2012-10-16

 

History

 

Subject was incorporated on 1999-11-15 with registered number 70452890 as Joint Stock Company in Taiwan.

 

Shareholders

 

Name

Subscription Shares

Fanggui Wei

66,541 

 

Zhang Men Investment Co., Ltd (Literal Translation)

 

 

9,989,023

 

Ai Da Yuan Investment Co., Ltd

(Literal Translation)

3,658,442

The information above is that of subject’s major shareholders.

 

Subsidiaries & Branches

It is introduced that subject three plant sites in Taiwan with total 9 dedicated production workshops all equipped with independent HVAC systems as well as producing equipments, while the details are not disclosed.

 

Personnel Information

Core Management

Directors

1

Name

Fanggui Wei

Position

Board Chairman

2

Name

Shiyi Wei

Position

Director

3

Name

Youzhi Ye

Position

Director

4

Name

Suying Chen

Position

Supervisor

 

Personnel Structure

 

Total Employees

About 50 employees

 

Operation Information

Offices & Factories

 

 

Headquarters

Add

No.2, Shih 4th Rd., Youth Industrial Park, Yangmei Township,

Taoyuan County 32657, Taiwan

 

Production Information

l         Subject is engaged in manufacture of BPC(bulk pharmaceutical chemicals)

l         It is introduced that subject supplies the service of customized production service 

l         It is introduced that subject has applied for 2 patents US 2007/0166809 and US 2007/0167641.

 

Purchase Information

l         The major registered activities of subject:

Business Code

Details

C801010 

Manufacture of basic chemicals

C801020 

Manufacture of raw materials for petrochemical industry

C802060 

Manufacture of Animal medicine

C802080  

Manufacture of Environmental health drug

C802120 

Manufacture of industrial additives

F102160 

Wholesales of accessary food

F107030 

Wholesales of cleaning products

F107080 

Wholesales of Environmental health drug

F107170 

Wholesales of industrial additives

F107990 

Wholesales of other chemical products (Pharmaceutical intermediates and essential oil)

F108040 

Wholesales of cosmetics

F108060 

Wholesales of B type medicine

F113030 

Wholesales of precise instrument

F207030 

Retails of cleaning products

F207080 

Retails of Environmental health medicine

F207170  

Retails of industrial additives

F207990 

Retails of other chemical products (Pharmaceutical intermediates and essential oil)

F213040 

Retails of  precise instrument

F401010 

International Trading Business

I103010 

enterprise operating and management consulting service

IC01010 

Pharmaceutical inspection industry

C808041 

Manufacture of Western medicine

C801030 

Manufacture of Precision chemical materials

 

l         Subject purchases raw materials and equipment both at home and abroad.

 

Sales Information

 

l         The subject is mainly engaged in sales of BPC(bulk pharmaceutical chemicals) such as MisoprostolLatanoprostBimatoprostTravoprostDinoprostAlprostadil and Epoprostenol, etc

l         Subject’s products are both sold in domestic and overseas market and it exports to Europe and USA, etc

l         It is introduced that over 90% of subject’s customers are overseas pharmaceutical factories

 

Products in Commercial Scale

Latanoprost (US DMF #18343; CAN DMF #2005-169; EDMF; Japan DMF; China DMF)
Bimatoprost (US DMF #21382; CAN DMF)
Travoprost (US DMF #22738)
Misoprostol 1% HPMC
Epoprostenol Sodium
Alprostadil
Dinoprostone
Dinoprost (PGF2α)

 

Products on R&D Pipeline

Lubiprostone
Cloprostenol Sodium
Treprostinil
Tiaprost
Prostacyclin & Analogs

 

Import and export right:

Import right

Yes

Export right

Yes

 

Settlements

Purchase

 

Domestic Purchase

Product

Payment Terms

Proportion

Raw materials and equipment, etc

COD, Credit Sales, etc

100%

 

Foreign Purchase

Product

Payment Terms

Proportion

Raw materials and equipment, etc

CBD, etc

100%

 

Sales

 

Domestic Markets

Product

Sales Terms

Proportion

BPC

CBD, etc

100%

 

Export

 

Product

Sales Terms

Proportion

BPC

CBD, etc

100%

 

Financial Information

 

Subject has no obligations to disclose its financial statements to the third party according to the relevant policy in Taiwan and the only source from which we can obtain the information is the subject itself.

Subject declined to disclose its financials citing the grounds of company’s confidentiality; from other source we can not obtain the relevant information, either.

 

Bankers

 

Subject did not introduce its bank details, thus we can not confirm the supplied banker Taiwan Business bank taipei city 103, Taiwan

 

Public Record

 

Mortgage

 

No chattel mortgage record of subject has been found within the recent 3 months.

 

Lawsuit

 

Up to date of reporting, no existing or latent litigation of the subject has been found.

 

Interview Details

 

Department

Sales department

 

 

 

 

FOREIGN EXCHANGE RATES

 

Currency

Unit

Indian Rupees

US Dollar

1

Rs.53.85

UK Pound

1

Rs.85.25

Euro

1

Rs.71.72

 

INFORMATION DETAILS

 

Report Prepared by :

NLM

 

RATING EXPLANATIONS

 

RATING

STATUS

 

 

PROPOSED CREDIT LINE

>86

Aaa

Possesses an extremely sound financial base with the strongest capability for timely payment of interest and principal sums

 

Unlimited

71-85

Aa

Possesses adequate working capital. No caution needed for credit transaction. It has above average (strong) capability for payment of interest and principal sums

 

Large

56-70

A

Financial & operational base are regarded healthy. General unfavourable factors will not cause fatal effect. Satisfactory capability for payment of interest and principal sums

 

Fairly Large

41-55

Ba

Overall operation is considered normal. Capable to meet normal commitments.

 

Satisfactory

26-40

B

Capability to overcome financial difficulties seems comparatively below average.

 

Small

11-25

Ca

Adverse factors are apparent. Repayment of interest and principal sums in default or expected to be in default upon maturity

 

Limited with full security

<10

C

Absolute credit risk exists. Caution needed to be exercised

 

 

Credit not recommended

--

NB

New Business

 

--

 

This score serves as a reference to assess SC’s credit risk and to set the amount of credit to be extended. It is calculated from a composite of weighted scores obtained from each of the major sections of this report. The assessed factors and their relative weights (as indicated through %) are as follows:

 

Financial condition (40%)            Ownership background (20%)                 Payment record (10%)

Credit history (10%)                    Market trend (10%)                                Operational size (10%)

 

 

PRIVATE & CONFIDENTIAL : This information is provided to you at your request, you having employed MIPL for such purpose. You will use the information as aid only in determining the propriety of giving credit and generally as an aid to your business and for no other purpose. You will hold the information in strict confidence, and shall not reveal it or make it known to the subject persons, firms or corporations or to any other. MIPL does not warrant the correctness of the information as you hold it free of any liability whatsoever. You will be liable to and indemnify MIPL for any loss, damage or expense, occasioned by your breach or non observance of any one, or more of these conditions

This report is issued at your request without any risk and responsibility on the part of MIRA INFORM PRIVATE LIMITED (MIPL) or its officials.